Walleye Trading’s ImmunityBio IBRX Stock Holding History

Walleye Trading’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-59,000	Closed	-$209	–	4690
2017 Q1	$209	Buy	+59,000	New	+$292K	﹤0.01%	2925

Other funds holding IBRX

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

VIA

Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Walleye Trading's IBRX Position: Q2 2017 in Review

Walleye Trading sold out of ImmunityBio (IBRX) in Q2 2017, closing a stake of 59,000 shares — an estimated $209 sold.

Walleye Trading first reported a position in IBRX in Q1 2017 and held it in 1 quarter. The position peaked at $209 in Q1 2017. 58 funds tracked by Wall St. Rank hold IBRX as of Q2 2017.

Walleye Trading reported no remaining ImmunityBio position as of Q2 2017 after selling out during the quarter.
Walleye Trading sold 59,000 ImmunityBio shares in Q2 2017, an estimated $209.
Walleye Trading first reported a position in ImmunityBio in Q1 2017 and held it in 1 quarter.
Walleye Trading's ImmunityBio position peaked at $209 in Q1 2017.
58 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2017.

Based on Walleye Trading's 13F filing for Q2 2017, filed 14 Aug 2017.